Rae William, Burke Georgina, Pinto Ashwin
Department of Immunology, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK.
J Neuroimmunol. 2016 Apr 15;293:82-85. doi: 10.1016/j.jneuroim.2016.02.015. Epub 2016 Feb 27.
Myasthenia gravis (MG) is an autoimmune neuromuscular disorder characterised by fatigable voluntary skeletal muscle weakness. The underlying pathogenesis is complex involving adaptive autoimmune responses. Azathioprine remains a first line broad acting immunosuppressant for MG. Due to varied clinical responses to azathioprine we aimed to investigate the relationship between azathioprine metabolites and symptom control. Mild correlations between Quantitative Myasthenia Gravis Score (QMG) vs. 6-thioguanine nucleotides (R=-0.317 p=0.186) and QMG vs. lymphocyte count (R=0.402 p=0.08) were found. Azathioprine metabolite measurement should be considered in MG patients with; pancytopenia, deranged liver function or recurrent infections.
重症肌无力（MG）是一种自身免疫性神经肌肉疾病，其特征为易疲劳的随意性骨骼肌无力。潜在的发病机制很复杂，涉及适应性自身免疫反应。硫唑嘌呤仍然是治疗重症肌无力的一线广泛使用的免疫抑制剂。由于对硫唑嘌呤的临床反应各不相同，我们旨在研究硫唑嘌呤代谢物与症状控制之间的关系。发现重症肌无力定量评分（QMG）与6-硫鸟嘌呤核苷酸之间存在轻度相关性（R=-0.317，p=0.186），QMG与淋巴细胞计数之间也存在轻度相关性（R=0.402，p=0.08）。对于全血细胞减少、肝功能紊乱或反复感染的重症肌无力患者，应考虑检测硫唑嘌呤代谢物。
